何志超,伍俊妍,邱凯锋

摘要(Abstract)：

<正>卫生部全国细菌耐药监测网(Mohnarin)数据显示,耐甲氧西林金黄色葡萄球菌(Methicillin-resistant Staphylococcus aureus,MRSA)分离率逐年上升,已成为医院感染重要的革兰阳性细菌[1]。万古霉素作为首个糖肽类抗菌药物,是具有三重杀菌机制的杀菌剂,通过抑制细菌细胞壁的合成、改变细菌细胞膜的通透性以及阻止细菌胞浆内RNA的合成而杀灭细菌,是治疗MRSA感染的首选

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 何志超,伍俊妍,邱凯锋

参考文献(References)：

• [1]肖永红,沈萍,魏泽庆,等.Mohnarin 2011年度全国细菌耐药监测[J].中华医院感染学杂志,2012,22(22):4946-4952.
• [2]Vancomycin HCl injection[S].APP Pharmaceuticals,LLC(per manufacturer),Schaumburg,IL,2011.
• [3]ALster Y,Herlin L,Lazar M,et al.Intraocular penetration of vancomycin eye drops after application to the medial canthus with closed lids[J].Br J Opthalmol,2000,84:300-302.
• [4]VANCOCIN(vancomycin HCl)oral capsules[S].Viro Pharma Incorporated(per FDA),Exton,PA,2011.
• [5]Evans WE,Schentag JJ,Jusko WJ,et al.Applied Pharmacokinetics:Principles of Therapeutic Drug Monitoring[M].3rd.Applied Therapeutics,Inc,Vancouver,WA,1992.
• [6]Leonard MB,Koren G,Stevenson DK,et al.Vancomycin pharmacokinetics in very low birth weight neonates[J].Pediatr Infect Dis J.1989,8:282-286.
• [7]Griffith RS.Vancomycin:continued clinical studies.Antibiotics Ann 1956,p 118.
• [8]Geraci JE,Heilman FR,Nichols DR,et al.Some laboratory and clinical experiences with a new antibiotic,vancomycin[J].Proc Staff Meet Mayo Clin,1956,31:564-582.
• [9]The United States Pharmacopeia[S].Rockville,Maryland:The United States Pharmacopeial Convention,2014.
• [10]Leong JVB,Boro MS,Winter ME.Determining vancomycin clearance in an overweight and obese population[J].Am J Health Syst Pharm,2011,68(7):599-603.
• [11]Saunders NJ.Why monitor peak vancomycin concentrations[J].Lancet,1994,44:1748-1750.
• [12]Ackerman BH.Clinical value of monitoring serum vancomycin concentrations[J].Clin Infect Dis,1994,9:1180-1181.
• [13]Rybak M,Lomaestro B,Rotschafer JC,et al.Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health-System Pharmacists,the Infectious Diseases Society of America,and the Society of Infectious Diseases Pharmacists[J].Am J Health Syst Pharm,2009,6:82-98.
• [14]Murphy JE,Gillespie DE,Bateman CV.Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters[J].Am J Health Syst Pharm,2006,3:2365-2370.
• [15]Matzke GR,Mc Gory RW,Halstenson CE,et al.Pharmacokinetics of vancomycin in patients with various degrees of renal function[J].Antimicrob Agents Chemother,1984,25:433-437.
• [16]Ariano RE,Fine A,Sitar DS,et al.Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis[J].Am J Kidney Dis,2005,6:681-687.
• [17]Isaacs E,et al.Pediatric Drug Dosage handbook,8th Edition[M],Ottawa,Canada:Winnipeg Health Sciences Center and CSHP,1998.